SQBG Sequential Brands Group, Inc. gains 20% Feb 28, 2018

Sequential Brands Group, Inc. owns, promotes, markets, and licenses a portfolio of consumer brands in the United States and internationally. It offers products in the apparel, footwear, eyewear, fashion accessories, and home goods categories under the Jessica Simpson, AND1, Avia, GAIAM, Joe's Jeans, Ellen Tracy, Emeril Lagasse, William Rast, Heelys, Revo, Caribbean Joe, DVS, The Franklin Mint, Linens N Things, SPRI, Nevados, and FUL brand names; and food, wine, pet supplies, magazines, books, and other print and digital content categories under the Martha Stewart brand name. The company licenses its brands through various distribution channels to retailers, wholesalers, and distributors. Sequential Brands Group, Inc. was incorporated in 1982 and is headquartered in New York, New York. http://www.priceseries.com/trade/SQBG-Sequential-Brands-Group-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018021420180228.html

MOSY MoSys, Inc. gains 20% Feb 28, 2018

MoSys, Inc., a fabless semiconductor company, together with its subsidiaries, develops and sells integrated circuits (ICs) for the high-speed networking, communications, storage, and computing markets. It offers Bandwidth Engine, a memory-dominated IC that has been designed to be a companion IC to packet processors; and LineSpeed IC product line, a non-memory, high-speed SerDes I/O device with clock data recovery, gearbox, and retimer functionality, which converts lanes of data received on line cards or by optical modules into various configurations and/or ensure signal integrity. The company serves networking and communications systems original equipment manufacturers. MoSys, Inc.markets and sells its products through sales and marketing personnel, sales representatives, and distributors in North America, Taiwan, Japan, China, rest of Asia, and Europe. The company was founded in 1991 and is headquartered in Santa Clara, California. http://www.priceseries.com/trade/MOSY-MoSys-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018021420180228.html

ENVA Enova International, Inc. gains 18% Feb 28, 2018

Enova International, Inc., a technology and analytics company, provides online financial services to non-prime credit consumers and small businesses in the United States, the United Kingdom, and Brazil. The company offers short-term consumer loans; line of credit accounts; installment loans; CSO programs, including credit-related services, such as arranging loans with independent third-party lenders and assisting in the preparation of loan applications and loan documents; and Bank programs comprising technology, loan servicing, and marketing services to a bank, as well as Enova Decisions, a analytics as a service that enables companies to take decisions about their own customers. It provides its services under the CashNetUSA, NetCredit, Pounds to Pocket, QuickQuid, On Stride Financial, Headway Capital, The Business Backer, and Simplic brands. The company was incorporated in 2011 and is headquartered in Chicago, Illinois. http://www.priceseries.com/trade/ENVA-Enova-International-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2018020120180228.html

AVP Avon Products, Inc. gains 16% Feb 28, 2018

Avon Products, Inc. manufactures and markets beauty and related products in Europe, the Middle East, Africa, South Latin America, North Latin America, and the Asia Pacific. The company offers beauty products, including skincare products that include personal care products, as well as fragrances and color cosmetics; and fashion and home products, such as fashion jewelry, watches, apparel, footwear, accessories, gift and decorative products, housewares, entertainment and leisure products, children's products, and nutritional products. It sells its products through direct selling by representatives. The company was founded in 1886 and is headquartered in London, the United Kingdom. http://www.priceseries.com/trade/AVP-Avon-Products-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018021420180228.html

ANTH Anthera Pharmaceuticals, Inc. gains 32% Feb 28, 2018

Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of immunoglobulin A nephropathy. The company was founded in 2004 and is headquartered in Hayward, CA, US. http://www.priceseries.com/trade/ANTH-Anthera-Pharmaceuticals-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2018021320180228.html

XL XL Group plc gains 20% Feb 27, 2018

XL Group Ltd, through its subsidiaries, operates as an insurance and reinsurance company worldwide. The company operates in two segments: Insurance and Reinsurance. The Insurance segment offers casualty programs comprising primary and excess casualty, environmental liability, and excess and surplus lines; energy, property, and construction insurance; professional lines, such as directors', officers' liability, errors and omissions, employment practices, crime, fiduciary, technology, and cyber liability coverages; and specialty lines, including the aviation and satellite, marine, fine art and specie, equine, livestock and aquaculture, crisis management, political risk, trade credit and life, and accident and health insurance products. The Reinsurance segment provides casualty reinsurance products, including general and professional liability, and automobile liability and workers' compensation; property reinsurance products comprising property catastrophe, property risk excess of loss, and property proportional; specialty reinsurance products, such as energy, marine, aviation, and space; and other reinsurance products, including fidelity, surety, trade credit, accident and health, mortgage, and political risk. It also writes whole account capital gearing quota share contracts on select syndicates at Lloyd's. The company markets its products and services to the industrial, commercial, professional, and insurance companies, as well as other enterprises through international, national, and regional producers, acting as the brokers and representatives of policyholders. XL Group Ltd was founded in 1986 and is based in Hamilton, Bermuda. http://www.priceseries.com/trade/XL-XL-Group-plc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018011920180227.html

VKTX Viking Therapeutics, Inc. gains 18% Feb 27, 2018

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for metabolic and endocrine disorders. Its lead clinical program includes VK0612, an orally available drug candidate for the treatment of type 2 diabetes. The company is also developing VK5211, an orally available drug candidate, which is in a Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. In addition, it is developing VK0214, a novel liver-selective thyroid hormone receptor beta agonist for lipid disorders, such as dyslipidemia and nonalcoholic steatohepatitis, as well as VK2809, an orally available, tissue, and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California. http://www.priceseries.com/trade/VKTX-Viking-Therapeutics-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2018020120180227.html

TWTR Twitter, Inc. gains 16% Feb 27, 2018

Twitter, Inc. operates as a global platform for public self-expression and conversation in real time. The company offers various products and services, including Twitter that allows users to create, distribute, and discover content; and Periscope, a mobile application that enables user to broadcast and watch video live with others. It also provides promoted products and services, such as promoted tweets, promoted accounts, and promoted trends, which enable its advertisers to promote their brands, products, and services. In addition, the company offers a set of tools, public APIs, and embeddable widgets for developers to contribute their content to its platform, and syndicate and distribute Twitter content across their properties and enhance their Websites and applications with Twitter content. Further, it provides subscription access to its public data feed for data partners. The company was founded in 2006 and is headquartered in San Francisco, California. http://www.priceseries.com/trade/TWTR-Twitter-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018020720180227.html

KONA Kona Grill, Inc. gains 18% Feb 27, 2018

Kona Grill, Inc. owns and operates upscale casual restaurants under the Kona Grill brand name. As of February 27, 2017, it owned and operated 45 restaurants in 23 states of the United States and Puerto Rico. Kona Grill, Inc. is based in Scottsdale, Arizona. http://www.priceseries.com/trade/KONA-Kona-Grill-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2018021320180227.html

IOVA Iovance Biotherapeutics, Inc. gains 103% Feb 27, 2018

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health for technologies relating to autologous TIL adoptive cell therapy products for the treatment of metastatic melanoma, lung, breast, bladder, and HPV-positive cancers; cooperative research and development agreement with the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's TIL, as well as for the treatment of cervical, head and neck, lung, bladder, and breast cancer; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech, Inc. to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. In addition, it has collaboration and license agreements with Medimmune, Inc. to conduct clinical and preclinical research in immuno-oncology; H. Lee Moffitt Cancer Center and Research Institute to research and develop adoptive TIL cell therapy; and PolyBioCept, AB to develop, manufacture, market, and genetically engineer TIL. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is headquartered in New York, New York. http://www.priceseries.com/trade/IOVA-Iovance-Biotherapeutics-Inc-stock-gains-103-percent-a-Trade-Record-by-priceSeries-2018010920180227.html

HTGM HTG Molecular Diagnostics, Inc. gains 15% Feb 27, 2018

HTG Molecular Diagnostics, Inc. develops and markets technology platforms that facilitate the routine use of complex molecular profiling. The company's HTG Edge and HTG EdgeSeq platforms consist of instrumentation, consumables, and software analytics that are used in molecular profiling applications, including tumor profiling, biomarker development and prospectively, and molecular diagnostic testing. The company's platforms automate the molecular profiling of genes and gene activity using its nuclease protection chemistry on various biological samples. It provides molecular profiling panels targeting late stage drug development programs with potential breakthrough therapies, such as immuno-oncology. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors or sales agents in parts of Europe and internationally. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. http://www.priceseries.com/trade/HTGM-HTG-Molecular-Diagnostics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2018021220180227.html

UA Under Armour, Inc. gains 17% Feb 26, 2018

Under Armour, Inc., together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot, cold, and in between the extremes. It also provides various footwear products, including running, basketball, cleated, slides and performance training, and outdoor footwear. In addition, the company offers accessories, which include headwear, bags, and gloves; and digital fitness platform licenses and subscriptions, as well as digital advertising. Under Armour, Inc. primarily provides its products under the UA Logo, UNDER ARMOUR, UA, ARMOUR, HEATGEAR, COLDGEAR, ALLSEASONGEAR, PROTECT THIS HOUSE, and I WILL, as well as ARMOURBITE, ARMOURSTORM, ARMOUR FLEECE, ARMOUR BRA, UA RECORD, UA HEALTHBOX, and UNDER ARMOUR CONNECTED FITNESS brands. The company sells its products through wholesale channels, including national and regional sporting goods chains, independent and specialty retailers, department store chains, institutional athletic departments, and leagues and teams, as well as independent distributors; and directly to consumers through a network of brand and factory house stores, and Website. Under Armour, Inc. was founded in 1996 and is headquartered in Baltimore, Maryland. http://www.priceseries.com/trade/UA-Under-Armour-Inc-stock-gains-17-percent-a-Trade-Record-by-priceSeries-2018021220180226.html

I Intelsat S.A. gains 15% Feb 26, 2018

Intelsat S.A., through its subsidiaries, provides satellite communications services worldwide. The company offers a range of communications services to media companies, fixed and wireless telecommunications operators, data networking service providers for enterprise and mobile applications in the air and on the seas, multinational corporations, and ISPs; and commercial satellite communication services to the U.S. government and other military organizations and their contractors. It provides various on-network services, including transponder services; managed services that combine satellite capacity, teleport facilities, satellite communications hardware, and other ground facilities to provide managed and monitored broadband, trunking, video, and private network services to customers; and channel services primarily used for point-to-point bilateral services to telecommunications providers. The company also offers off-network and other services comprising transponder, mobile satellite, and other services. In addition, it offers satellite-related consulting and technical services that include the lifecycle of satellite operations and related infrastructure, from satellite and launch vehicle procurement through telemetry and commanding services, and related equipment sale services to other satellite operators. The company was founded in 1964 and is headquartered in Luxembourg, Luxembourg. Intelsat S.A. is a subsidiary of Serafina S.A. http://www.priceseries.com/trade/I-Intelsat-SA-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2018021220180226.html

VSTO Vista Outdoor Inc. gains 20% Feb 22, 2018

Vista Outdoor Inc. designs, manufactures, and markets consumer products for the outdoor sports and recreation markets worldwide. The company's Shooting Sports segment designs, develops, produces, and sources ammunition for the hunting and sport shooting enthusiast markets, as well as for local law enforcement, the United States government, and international markets under the Federal Premium, Speer, American Eagle, Blazer, CCI, Estate Cartridge, Stevens, Fusion, Savage Arms, Savage Range Systems, Force on Force, and Independence brands; and provides firearms products, such as centerfire rifles, rimfire rifles, shotguns, and range systems. Its Outdoor Products segment offers archery/hunting accessories, such as hunting arrows, game calls, hunting blinds, game cameras, and waterfowl decoys; eyewear and sport protection products comprising safety and protective eyewear, fashion and sports eyewear, and helmets; golf products, including laser rangefinders; and hydration products consisting of hydration packs and water bottles. This segment also offers optics products, such as binoculars, riflescopes, and telescopes; shooting accessories, including reloading equipment, clay targets, and premium gun care products; tactical products comprising holsters, duty gear, bags, and packs; and water sports products, such as stand up paddle boards. It provides its products under the Alliant Powder, Bee Stinger, BLACKHAWK!, Bolle, Bushnell, Butler Creek, CamelBak, Cebe, Champion Target, Eagle, Final Approach, Gold Tip, GunMate, Gunslick Pro, Hoppe's, Jimmy Styks, M-Pro 7, Millett, Night Optics, Outers, Primos, RCBS, Redfield, Serengeti, Simmons, Stoney Point, Tasco, Uncle Mike's, and Weaver brand names. The company sells its products to outdoor enthusiasts, hunters and recreational shooters, athletes, and law enforcement and military professionals through various mass, specialty, and independent retailers. The company was incorporated in 2014 and is headquartered in Farmington, Utah. http://www.priceseries.com/trade/VSTO-Vista-Outdoor-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2018020720180222.html

JNP Juniper Pharmaceuticals, Inc. gains 38% Feb 22, 2018

Juniper Pharmaceuticals, Inc., a women's health therapeutic company, focuses on developing therapeutics that address unmet medical needs in women's health. The company develops its products using its drug delivery technologies, including bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa for sustained and controlled delivery of active drug product; and a novel intra-vaginal ring (IVR) technology. It markets CRINONE, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. The company is also developing COL-1077, a lidocaine bioadhesive gel, which is in Phase 2b clinical trial for use as an acute use anesthetic for pain from minimally invasive gynecological procedures. Its products in preclinical development include JNP-0101, an oxybutynin IVR to treat overactive bladder in women; JNP-0201, a product candidate with natural progesterone and natural estradiol for used in hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone IVR used for the prevention of preterm birth. In addition, Juniper Pharmaceuticals, Inc. provides pharmaceutical development, clinical trial manufacturing, analytical, and consulting services. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts. http://www.priceseries.com/trade/JNP-Juniper-Pharmaceuticals-Inc-stock-gains-38-percent-a-Trade-Record-by-priceSeries-2018012220180222.html

SNAP Snap Inc. gains 32% Feb 21, 2018

N/A http://www.priceseries.com/trade/SNAP-Snap-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2018020620180221.html

TAT Transatlantic Petroleum Ltd gains 23% Feb 20, 2018

TransAtlantic Petroleum, Ltd., an oil and natural gas company, engages in the acquisition, exploration, development, and production of oil and natural gas. As of December 31, 2016, the company had interests in 11 onshore and offshore exploration licenses and 25 onshore production leases covering an area of 395,000 net acres in Turkey; and a production concession covering an area of approximately 165,000 net undeveloped acres in Bulgaria. TransAtlantic Petroleum, Ltd. was founded in 1985 and is based in Addison, Texas. http://www.priceseries.com/trade/TAT-Transatlantic-Petroleum-Ltd-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2018012320180220.html

DGAZ 3X Inverse Natural Gas ETN Velocityshares gains 35% Feb 20, 2018

The investment seeks to replicate, net of expenses, three times the opposite (inverse) of this GSCI Natural Gas Index ER. The index comprises futures contracts on a single commodity and is calculated according to the methodology of the S&P GSCI Index. http://www.priceseries.com/trade/DGAZ-3X-Inverse-Natural-Gas-ETN-Velocityshares-stock-gains-35-percent-a-Trade-Record-by-priceSeries-2018013120180220.html

GENE Genetic Technologies Ltd gains 42% Feb 15, 2018

Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. In addition, the company offers BREVAGen, a diagnostic test that informs clinicians and patients about individual, non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia. http://www.priceseries.com/trade/GENE-Genetic-Technologies-Ltd-stock-gains-42-percent-a-Trade-Record-by-priceSeries-2018010420180215.html

BSPM Biostar Pharmaceuticals, Inc. gains 23% Feb 15, 2018

Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China. The company principally offers Xin Ao Xing Oleanolic Acid capsule, an OTC medicine for chronic hepatitis B. Its product line also includes 12 other OTC products and 17 prescription-based pharmaceuticals. The company's OTC products also comprise Ganwang compound paracetamol and amantadine hydrochloride capsule for the relief of common cold, runny nose, sore throat, headache, and fever; Tianqi Dysmenorrhea capsule, a traditional Chinese medicine used for pain and other symptoms associated with menstruation; Deafness Tongqiao pills for hepatobiliary Huosheng, head swelling, deafness and tinnitus, ear pus, dry stool, and urine-yellow; Wenweishu capsules for the treatment of chronic gastritis and pain of epigastric cold; Zhitongtougu ointment for treating joint pain, swelling, tenderness, or dysfunction; and Chuzhang Zehaifu tablets for cataract. Its prescription pharmaceutical products include Danshen granules; Taohuasan pediatric medicines; Jingang tablets; Danxiang Rhinitis tablets; Yanlixiao capsules; Piracetam tablets; Huangyangning tablets; Hyperthyroidism capsules; Fosfomycin Calcium capsules; Qianlietong capsules; Yituo Erythromycin particles; Danshen tablets; Hernia belt; Tangning capsule; Yizi capsule; Shengjing Capsule; Aoxing Ointment; Muxiang Shunqi pills; Sifangwei capsules; and Aspirin Enteric-coated tablets. The company also operates a Website that serves as Internet-based China Hepatitis Internet hospital, which offers HBV patients with information on HBV and treatment options, as well as methods to purchase HBV medicines. Biostar Pharmaceuticals, Inc. sells its products through distributors and a network of sales people in approximately 28 provinces. The company was incorporated in 2007 and is headquartered in Xianyang, the People's Republic of China. http://www.priceseries.com/trade/BSPM-Biostar-Pharmaceuticals-Inc-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2018020620180215.html

VIIX Vs VIX Short Term gains 45% Feb 14, 2018

Credit Suisse Group AG, together with its subsidiaries, provides various financial services worldwide. It operates through Swiss Universal Bank, International Wealth Management, Asia Pacific, Global Markets, and Investment Banking & Capital Markets segments. The company offers advisory and financial solutions, such as structured advisory, investment advisory, discretionary asset management, mergers and acquisitions transactions, corporate sales and restructurings, divestitures, takeover defense strategies, equity and fixed income sales, trading, debt and equity securities, spin-offs, debt and equity underwritings, private placements, and derivative products, as well as proprietary and third-party products and services. It also provides traditional and structured lending, payment, foreign exchange, capital goods leasing, trade finance, export finance, factoring, ship and aviation finance services; and fund solutions and fund-linked services. In addition, the company offers investment solutions and services to pension funds, governments, foundations and endowments, corporations, and individuals; and global securities sales, trading and execution, prime brokerage, and investment research services. It operates 401 offices and branches. The company offers its products and services to private, corporate, institutional, ultra-high-net-worth and high-net-worth individuals, small and medium-sized enterprises, institutional clients, and financial institutions, as well as affluent and retail clients. Credit Suisse Group AG was founded in 1856 and is based in Zurich, Switzerland. http://www.priceseries.com/trade/VIIX-Vs-VIX-Short-Term-stock-gains-45-percent-a-Trade-Record-by-priceSeries-2018020120180214.html

QBAK Qualstar Corporation gains 37% Feb 13, 2018

Qualstar Corporation designs, develops, manufactures, and sells power supplies under the N2Power brand; and data storage systems under the Qualstar brand worldwide. It offers switching power supplies that are used to convert AC line voltage to DC voltages, or DC voltages to other DC voltages for use in electronic equipment, such as telecommunications equipment, machine tools, routers, switches, wireless systems, and gaming devices. The company also provides automated magnetic tape libraries used to store, retrieve, and manage electronic data primarily in network computing environments, as well as provide data storage solutions for organizations requiring backup, recovery, and archival storage of critical data. Its tape libraries include cartridge tape drives, tape cartridges, and robotics that move the cartridges from their storage locations to the tape drives under software control. The company serves original equipment manufacturers, information technology departments, and small and medium businesses through distributor and reseller network, distributors, and independent outside sales representatives. Qualstar Corporation was founded in 1984 and is headquartered in Simi Valley, California. http://www.priceseries.com/trade/QBAK-Qualstar-Corporation-stock-gains-37-percent-a-Trade-Record-by-priceSeries-2018012320180213.html

AFMD Affimed N.V. gains 19% Feb 13, 2018

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. Its lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. The company's product candidates also include AFM11, a T-cell TandAb, which is in Phase I clinical trial for the treatment of various CD19+ B-cell malignancies, including non-Hodgkin Lymphoma, acute lymphocytic leukemia, and chronic lymphocytic leukemia; and AFM21, a TandAb program in preclinical development that binds epidermal growth factor receptor variant III for solid tumors, as well as for patients with glioblastoma, hormone refractory prostate cancer, and head and neck cancer. Its AFM21 product also binds CD3, directing T-cells to destroy tumor cells that carry EGFRvIII. Affimed N.V. has license agreements with Amphivena Therapeutics, Inc. and Xoma Ireland Limited; research funding agreement with The Leukemia & Lymphoma Society; and clinical research collaboration with Merck & Co Inc. It also has a strategic clinical development and commercialization collaboration with The University of Texas MD Anderson Cancer Center to evaluate Affimed's TandAb technology in combination with MD Anderson's natural killer cell product. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany. http://www.priceseries.com/trade/AFMD-Affimed-NV-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2018020120180213.html

SNSS Sunesis Pharmaceuticals, Inc. gains 40% Feb 9, 2018

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein Bruton's tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California. http://www.priceseries.com/trade/SNSS-Sunesis-Pharmaceuticals-Inc-stock-gains-40-percent-a-Trade-Record-by-priceSeries-2018010920180209.html

CFRX ContraFect Corporation gains 18% Feb 9, 2018

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York. http://www.priceseries.com/trade/CFRX-ContraFect-Corporation-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2018012620180209.html

OGEN Oragenics, Inc. gains 32% Feb 8, 2018

Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in initiation of Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its products also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has license agreement with Intrexon Corporation to use its technology to develop lantibiotics; and Intrexon Corporation and its wholly owned subsidiary, Actobiotics NV to use their intellectual property to develop AG013. It also has license agreement with LPThera LLC to develop LPT3-04 weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida. http://www.priceseries.com/trade/OGEN-Oragenics-Inc-stock-gains-32-percent-a-Trade-Record-by-priceSeries-2018012220180208.html

MNOV MediciNova, Inc. gains 16% Feb 8, 2018

MediciNova, Inc., a biopharmaceutical company, focuses on acquiring and developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company's product candidate includes MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for the treatment of neurological disorders, including primary and secondary progressive multiple sclerosis; amyotrophic lateral sclerosis; and substance dependence and addiction, including methamphetamine, opioid, and alcohol dependence. Its product pipeline also comprises MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, such as nonalcoholic steatohepatitis, idiopathic pulmonary fibrosis, and other fibrotic diseases; MN-221 (bedoradrine), a ß2-adrenergic receptor agonist for the treatment of acute exacerbation of asthma; and MN-029 (denibulin), a tubulin binding agent to treat solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California. http://www.priceseries.com/trade/MNOV-MediciNova-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018012520180208.html

GERN Geron Corporation gains 23% Feb 8, 2018

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California. http://www.priceseries.com/trade/GERN-Geron-Corporation-stock-gains-23-percent-a-Trade-Record-by-priceSeries-2018012220180208.html

ENTA Enanta Pharmaceuticals, Inc. gains 33% Feb 8, 2018

Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on four disease targets: Hepatitis C virus (HCV), Hepatitis B virus (HBV), Non-alcoholic Steatohepatitis (NASH), and Respiratory Syncytial Virus (RSV). Its lead product is paritaprevir, a protease inhibitor designed for use against HCV. The company also develops HCV protease inhibitor in phase III development with AbbVie, as well as a HCV program using a different class of molecules known as cyclophilin inhibitors. In addition, it has a program in non-alcoholic steatohepatitis; and discovers programs in other areas of viral infection and liver disease. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with AbbVie to develop and commercialize HCV NS3 and NS3/4A protease inhibitors. The company was founded in 1995 and is headquartered in Watertown, Massachusetts. http://www.priceseries.com/trade/ENTA-Enanta-Pharmaceuticals-Inc-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2018011620180208.html

CATM Cardtronics, Inc. gains 19% Feb 7, 2018

Cardtronics plc provides automated consumer financial services through its network of automated teller machines (ATMs) and multi-function financial services kiosks. The company offers cash dispensing and bank account balance inquiries, as well as other automated consumer financial services, including bill payments, check cashing, remote deposit capture, and money transfer services. It also provides managed services solutions, such as monitoring, maintenance, cash management, communications, and customer service; and owns and operates electronic funds transfer transaction processing platforms that provide transaction processing services to other ATMs under managed services arrangements. In addition, the company owns and operates Allpoint network, a surcharge-free ATM network, which offers surcharge-free ATM access to participating banks, credit unions, and stored-value debit card issuers. As of February 9, 2017, it provided services to approximately 225,000 ATMs in North America, Europe, and the Asia-Pacific. The company was founded in 1989 and is headquartered in Houston, Texas. http://www.priceseries.com/trade/CATM-Cardtronics-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2018010820180207.html

WRLD World Acceptance Corporation gains 24% Feb 6, 2018

World Acceptance Corporation engages in small-loan consumer finance business in the United States and Mexico. The company offers short-term small and medium-term larger installment loans, as well as related credit insurance and ancillary products and services to individuals. It also provides automobile club memberships to its borrowers; income tax return preparation and electronic filing services; and electronic products and appliances to its borrowers. In addition, the company markets and sells credit life, credit accident and health, credit property, and unemployment insurance in connection with its loans; and develops and markets software products to financial services companies. It serves individuals with limited access to other sources of consumer credit, such as banks, credit unions, other consumer finance businesses, and credit card lenders. As of March 31, 2016, the company operated 1,339 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, and Wisconsin, as well as in Mexico. World Acceptance Corporation was founded in 1962 and is headquartered in Greenville, South Carolina. http://www.priceseries.com/trade/WRLD-World-Acceptance-Corporation-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2018011920180206.html

TVIX Vs 2X VIX Short Term gains 53% Feb 6, 2018

Credit Suisse Group AG, together with its subsidiaries, provides various financial services worldwide. It operates through Swiss Universal Bank, International Wealth Management, Asia Pacific, Global Markets, and Investment Banking & Capital Markets segments. The company offers advisory and financial solutions, such as structured advisory, investment advisory, discretionary asset management, mergers and acquisitions transactions, corporate sales and restructurings, divestitures, takeover defense strategies, equity and fixed income sales, trading, debt and equity securities, spin-offs, debt and equity underwritings, private placements, and derivative products, as well as proprietary and third-party products and services. It also provides traditional and structured lending, payment, foreign exchange, capital goods leasing, trade finance, export finance, factoring, ship and aviation finance services; and fund solutions and fund-linked services. In addition, the company offers investment solutions and services to pension funds, governments, foundations and endowments, corporations, and individuals; and global securities sales, trading and execution, prime brokerage, and investment research services. It operates 401 offices and branches. The company offers its products and services to private, corporate, institutional, ultra-high-net-worth and high-net-worth individuals, small and medium-sized enterprises, institutional clients, and financial institutions, as well as affluent and retail clients. Credit Suisse Group AG was founded in 1856 and is based in Zurich, Switzerland. http://www.priceseries.com/trade/TVIX-Vs-2X-VIX-Short-Term-stock-gains-53-percent-a-Trade-Record-by-priceSeries-2018020220180206.html

NKTR Nektar Therapeutics gains 15% Feb 6, 2018

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. The company offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A. Its drug candidates in clinical development stage comprises BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-214 that is in Phase 1/2 stage to treat cancer; NKTR-181 that is in Phase III clinical trial for treating chronic pain; and NKTR-358 to treat autoimmune diseases. The company's drug candidates in clinical development stage also include ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as completed Phase II clinical trial stage for refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat refractory solid tumor cancers, which has completed Phase I clinical trial. In addition, it holds license, manufacturing, and supply agreements with Ophthotech Corporation for Fovista; and UCB Pharma for dapirolizumab pegol. Further, the company holds a range of license, manufacturing, and supply agreements with other biotechnology and pharmaceutical companies, including Amgen Inc.; Allergan, Inc.; Merck & Co., Inc.; Pfizer, Inc.; and F. Hoffmann-La Roche Ltd (Roche). Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California. http://www.priceseries.com/trade/NKTR-Nektar-Therapeutics-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2018011720180206.html

MDGL Madrigal Pharmaceuticals Inc gains 27% Feb 6, 2018

Synta Pharmaceuticals Corp. focuses on the research, development, and commercialization of novel oncology medicines for cancer patients. Its clinical stage drug candidate in oncology is ganetespib, an Hsp90 inhibitor, which is in Phase II clinical trials to evaluate the combination of ganetespib and paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer; and in Phase I/II trial in combination with the mTOR inhibitor sirolimus in patients with refractory sarcoma, including malignant peripheral nerve sheath tumors. The company's drug candidate in its Hsp90-inhibitor Drug Conjugate program is STA-12-8666, which is in preclinical trials for chemotherapy irinotecan. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts. http://www.priceseries.com/trade/MDGL-Madrigal-Pharmaceuticals-Inc-stock-gains-27-percent-a-Trade-Record-by-priceSeries-2018011720180206.html

MBT Mobile TeleSystems OJSC gains 15% Feb 6, 2018

Public Joint-Stock Company Mobile TeleSystems provides telecommunication services in Russia and the Commonwealth of Independent States. The company offers voice and data transmission, Internet access, pay TV, and various value added services through wireless and fixed lines, as well as sells equipment, accessories, and handsets. It also provides system integration services and complex IT solutions. The company serves approximately 100 million mobile subscribers. It also operates 13 retail shops in Perm, Kizel, Aleksandrovsk, Berezniki, Vereshchagino, and Lysva. The company was founded in 1993 and is based in Moscow, the Russian Federation. Public Joint-Stock Company Mobile TeleSystems is a subsidiary of Sistema Finance S.A. http://www.priceseries.com/trade/MBT-Mobile-TeleSystems-OJSC-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2017122820180206.html

DST DST Systems, Inc. gains 30% Feb 6, 2018

DST Systems, Inc. provides technology-based information processing and servicing solutions in the United States, the United Kingdom, Canada, Australia, and internationally. The company's Financial Services segment provides investor, investment, advisor/intermediary, and asset distribution services to companies in the financial services industry. This segment provides customers information processing solutions, such as tracking of purchases, redemptions, and exchanges and transfers of shares; maintaining investor identification and ownership records; reconciling cash and share activity; processing dividends; reporting sales; performing tax and other compliance functions; and providing information for printing of investor trade confirmations, statements, and year-end tax forms. Its Healthcare Services segment offers healthcare organizations a range of medical and pharmacy solutions for information processing, quality of care, cost management, and payment integrity needs; and healthcare solutions, including claims adjudication, benefit management, care management, business intelligence, and other ancillary services. The company's Investments and Other segment invests in equity securities, private equity investments, and other financial interests, as well as owns real estate joint ventures for lease. DST Systems, Inc. was founded in 1968 and is headquartered in Kansas City, Missouri. http://www.priceseries.com/trade/DST-DST-Systems-Inc-stock-gains-30-percent-a-Trade-Record-by-priceSeries-2018010420180206.html

CASM CAS Medical Systems, Inc. gains 75% Feb 6, 2018

CAS Medical Systems, Inc., a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide. The company provides FORE-SIGHT tissue oximeter monitors, sensors, and accessories, as well as offers FORE-SIGHT ELITE monitors; and traditional monitoring products, such as non-invasive blood pressure measurement technologies under the MAXNIBP and MAXIQ brand names, as well as provides monitor service and repair. It markets products through its own sales force, distributors, manufacturers' representatives, and original equipment manufacturers, as well as through hospital, surgery center and outpatient facility, homecare, veterinary, and emergency medical distribution channels. CAS Medical Systems, Inc. was incorporated in 1984 and is headquartered in Branford, Connecticut. http://www.priceseries.com/trade/CASM-CAS-Medical-Systems-Inc-stock-gains-75-percent-a-Trade-Record-by-priceSeries-2017122120180206.html

ADVM Adverum Biotechnologies, Inc. gains 51% Feb 6, 2018

Avalanche Biotechnologies, Inc., a gene therapy company, engages in discovering and developing novel medicines that offer therapeutic benefit to patients suffering from chronic or debilitating disease. It primary focuses on developing AVA-101, which is in a Phase IIa trial for the treatment of wet age-related macular degeneration (AMD). The company is also developing AVA-201, a product candidate for the prevention of wet AMD; AVA-311 that is in preclinical studies for the treatment of juvenile X-linked retinoschisis, a rare genetic disease of the retina with no approved therapy; and AVA-322 and AVA-323 for the treatment of color vision deficiency. Avalanche Biotechnologies, Inc. has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products. The company was founded in 2006 and is headquartered in Menlo Park, California. http://www.priceseries.com/trade/ADVM-Adverum-Biotechnologies-Inc-stock-gains-51-percent-a-Trade-Record-by-priceSeries-2018011620180206.html

VTVT vTv Therapeutics Inc. gains 24% Feb 5, 2018

Biotech developing treatments for Alzheimer's disease and type 2 diabetes. http://www.priceseries.com/trade/VTVT-vTv-Therapeutics-Inc-stock-gains-24-percent-a-Trade-Record-by-priceSeries-2018012220180205.html

PBR Petroleo Brasileiro S.A.- Petrobras gains 33% Feb 5, 2018

Petroleo Brasileiro S.A.?Petrobras, together with its subsidiaries, engages in the exploration, exploitation, and production of oil and gas, and energy in Brazil and internationally. The company operates in four segments: Exploration and Production, Supply, Gas and Energy, and Distribution. The Exploration and Production segment engages in the exploration, development, and production of oil, liquefied natural gas, and natural gas in Brazil; and sells petroleum and bye products produced in natural gas processing plants. The Supply segment involves in the refining, logistic, transportation, and sale of oil products, petroleum, and alcohol. It also holds interests in petrochemical companies and fertilizer plants. The Gas and Energy segment involves in the purchase, sale, and transportation of natural gas produced in or imported into Brazil. This segment also generates and distributes electric power; and holds interests in national gas transporters and distributors, and thermoelectric power stations. The Distribution segment distributes oil products, fuel alcohol, and compressed natural gas in Brazil. The company also engages in the exploration, production, supply, and distribution of oil and gas in the Americas, Africa, Europe, and Asia. Petroleo Brasileiro was founded in 1953 and is headquartered in Rio de Janeiro, Brazil. http://www.priceseries.com/trade/PBR-Petroleo-Brasileiro-SA--Petrobras-stock-gains-33-percent-a-Trade-Record-by-priceSeries-2017122020180205.html

OHGI One Horizon Group, Inc. gains 22% Feb 5, 2018

One Horizon Group, Inc., through its subsidiaries, develops, and licenses software solutions to telecommunications operators in China, Asia, Europe, the Russian Federation, and the United States. The company develops Horizon Platform, a bandwidth-efficient voice over Internet protocol platform for smartphones and tablets; and Horizon Call, a mobile application, which enables bandwidth-efficient VoIP calls over a smartphone using a 2G/EDGE, 3G, 4G/LTE, WiFi, or WiMax connection. It provides data applications, including multi-media messaging and mobile advertising under the Aishuo brand name; and software maintenance services. The company licenses its software solutions to telecommunications network operators and service providers in the mobile, fixed line, cable TV, and satellite communications markets. The company is based in Limerick, Ireland. http://www.priceseries.com/trade/OHGI-One-Horizon-Group-Inc-stock-gains-22-percent-a-Trade-Record-by-priceSeries-2018012220180205.html

NYT New York Times Company (The) gains 19% Feb 5, 2018

The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide. The company provides The New York Times (The Times), a daily and Sunday newspapers in the United States, as well as international edition of The Times; and operates the NYTimes.com Website. It also transmits articles, graphics, and photographs from The Times and other publications to approximately 2000 newspapers, magazines, and Websites; and offers product licensing, book development, news digests, and rights and permissions, as well as is involved in online retail store business. In addition, the company engages in NYT Live business, a platform for its live journalism; and digital archive distribution, which licenses electronic archive databases to resellers of that information in the business, professional, and library markets. Further, it develops mobile applications, including NYT cooking, Crossword, and others; and operates product review and recommendation Websites that serve as a guide to technology gear, home products, and other consumer goods. The New York Times Company was founded in 1896 and is headquartered in New York, New York. http://www.priceseries.com/trade/NYT-New-York-Times-Company-The-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2018010520180205.html

NOW ServiceNow, Inc. gains 18% Feb 5, 2018

ServiceNow, Inc. provides enterprise cloud computing solutions that define, structure, manage, and automate services for enterprises worldwide. The company offers service management solutions for customer support, human resources, security operations, and other enterprise departments. It operates ServiceNow platform that provides workflow, configuration management database, service catalog, service portal, knowledge management, reporting and analytics, data benchmarking, visual task boards, built-in and optional encryption capabilities, and collaboration and developer tools. The company also provides information technology (IT) solutions, such as IT service management product suite for enterprise's employees, customers, and partners; IT operations management that connects a customer's physical and cloud-based IT infrastructure with applications and platforms; and IT business management product suite that enables customers to manage their IT priorities. In addition, it offers customer service management product for customer service cases and requests; HR service management product; and security operation management product for security operations management requirements of third-party. Further, the company provides professional services, training services and certification programs, and customer support services. It serves enterprises in various industries, including financial services, consumer products, IT services, healthcare, and technology. The company sells products through its direct sales team, as well as indirectly through third-party channels by partnering with systems integrators, managed services providers, and resale partners. The company was formerly known as Service-now.com and changed its name to ServiceNow, Inc. in May 2012. ServiceNow, Inc. was founded in 2004 and is headquartered in Santa Clara, California with additional offices in North America, South America, Europe, and Asia. http://www.priceseries.com/trade/NOW-ServiceNow-Inc-stock-gains-18-percent-a-Trade-Record-by-priceSeries-2017121320180205.html

NFLX Netflix, Inc. gains 28% Feb 5, 2018

Netflix, Inc., an Internet television network, engages in the Internet delivery of television (TV) shows and movies on various Internet-connected screens. The company operates in three segments: Domestic Streaming, International Streaming, and Domestic DVD. It offers members with the ability to receive streaming content through a host of Internet-connected screens, including TVs, digital video players, television set-top boxes, and mobile devices. The company also provides DVDs-by-mail membership services. It serves approximately 93 million streaming members in 190 countries. Netflix, Inc. was founded in 1997 and is headquartered in Los Gatos, California. http://www.priceseries.com/trade/NFLX-Netflix-Inc-stock-gains-28-percent-a-Trade-Record-by-priceSeries-2018010220180205.html

KURA Kura Oncology, Inc. gains 19% Feb 5, 2018

Developing in-licensed protein inhibitors for solid tumors and blood cancers. http://www.priceseries.com/trade/KURA-Kura-Oncology-Inc-stock-gains-19-percent-a-Trade-Record-by-priceSeries-2018011120180205.html

KMPH KemPharm, Inc. gains 46% Feb 5, 2018

KemPharm, Inc., a clinical-stage specialty pharmaceutical company, discovers and develops new proprietary prodrugs in the United States. Its lead product candidates are KP415, an extended release d-threo-methylphenidate product candidate for the treatment of ADHD; and KP201/IR, an IR formulation of KP201, a prodrug of hydrocodone and acetaminophen for the treatment of acute pain. The company is also involved in developing KP511/ER, a prodrug of hydromorphone for the management of pain; KP511/IR for the short duration management of acute pain; KP606/IR, an IR formulation of KP606, a prodrug of oxycodone for the management of moderate to severe pain; KP746, a prodrug of oxymorphone for the management of moderate to severe pain; and KP303, a prodrug of quetiapine for the treatment of central nervous system disorders. KemPharm, Inc. was founded in 2006 and is headquartered in Coralville, Iowa. http://www.priceseries.com/trade/KMPH-KemPharm-Inc-stock-gains-46-percent-a-Trade-Record-by-priceSeries-2017122720180205.html

KEN Kenon Holdings Ltd. gains 34% Feb 5, 2018

Kenon Holdings Ltd., through its subsidiaries, owns, develops, and operates power generation and distribution facilities primarily in Latin America, the Caribbean, and Israel markets. It also designs, manufactures, distributes, and services passenger vehicles through a network of independent authorized retail dealers in the People's Republic of China. As of December 31, 2015, the company's dealerships included 86 operational point of sales. In addition, it develops and owns a proprietary natural gas-to-liquid technology process. The company is based in Singapore. http://www.priceseries.com/trade/KEN-Kenon-Holdings-Ltd-stock-gains-34-percent-a-Trade-Record-by-priceSeries-2017122920180205.html

GLPG Galapagos NV gains 16% Feb 5, 2018

Belgian biotech developing new treatments for inflammatory diseases. http://www.priceseries.com/trade/GLPG-Galapagos-NV-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018010520180205.html

CTMX CytomX Therapeutics, Inc. gains 16% Feb 5, 2018

Preclinical biotech developing tumor-activated cancer immunotherapies. http://www.priceseries.com/trade/CTMX-CytomX-Therapeutics-Inc-stock-gains-16-percent-a-Trade-Record-by-priceSeries-2018010320180205.html

CCXI ChemoCentryx, Inc. gains 42% Feb 5, 2018

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe Crohn's diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California. http://www.priceseries.com/trade/CCXI-ChemoCentryx-Inc-stock-gains-42-percent-a-Trade-Record-by-priceSeries-2018010320180205.html